Conditions · Alzheimer's disease & early-stage dementia
Alzheimer's disease & early-stage dementia — frontier options in Illinois
Prefer to look first? Browse the live map without signing up.
30 open options
- TRIALPHASE3RECRUITING
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
KarXT — 429 sites
- TRIALPHASE3RECRUITING
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Acoramidis · Placebo oral tablet — 104 sites
- TRIALNANOT_YET_RECRUITING
Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 2
Project 2, Phase 2: Intelligent Adaptive System — 3 sites
- TRIALNANOT_YET_RECRUITING
ALDH2 Genetic Testing in East Asian Community
Genetic Test Results Return · Alcohol Flushing Education — 1 site
- TRIALNANOT_YET_RECRUITING
Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 1
Project 1 - Phase 2: VR Program for Social, Activity, and Cognitive Engagement · Project 1 - Phase 2: Tablet for Social, Activity, and Cognitive Engagement — 3 sites
- TRIALNARECRUITING
OTC Hearing Aid and MCI
Over the counter hearing aid · Communication Strategies Information/Counseling — 3 sites
- TRIALNARECRUITING
Race-Based Stress and Cognitive Training for MCI
Race Based Stress and Empowerment Focused Compensatory Cognitive Training for Mild Cognitive Impairment (RBSEF-CCT-MCI) · Motivationally Enhanced Compensatory Cognitive Training for Mild Cognitive Impairment (ME-CCT) — 1 site
- TRIALPHASE3RECRUITING
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
Donanemab · Placebo — 59 sites
- TRIALNARECRUITING
Home Based Functional Balance Intervention for Multiple Sclerosis
Multicomponent balance intervention consisting of four components including dual-tasking, functional strength, vestibular and dynamic balance. · Stretching — 1 site
- TRIALPHASE3RECRUITING
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
KarXT · KarX-EC · Placebo — 119 sites
- TRIALPHASE2RECRUITING
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
MK-2214 · Placebo — 80 sites
- TRIALPHASE2NOT_YET_RECRUITING
RQC for the Prevention of Alzheimer's Disease and Retinal Amyloid-β
Resveratrol, Quercetin, and Curcumin (RQC) · Curcumin — 1 site
- TRIALPHASE2 / PHASE3RECRUITING
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Remternetug · Matching Placebo (Remternetug) — 37 sites
- TRIALPHASE3RECRUITING
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
No Intervention — 229 sites
- TRIALPHASE2 / PHASE3RECRUITING
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Remternetug (SC) · Matching Placebo (Remternetug) — 37 sites
- TRIALNARECRUITING
Central Auditory Processing Modulation Underlying Anxiety Reduction Using Clinically Designed Improvisatory Music
Clinically Designed Improvisatory Music · Listening to Storytelling — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
rTMS to Improve Cognition in Parkinson's
MagVenture MagProX100 stimulator (MagVenture, Falun, Denmark) · MagVenture MagProX100 stimulator (MagVenture, Falun, Denmark) — 2 sites
- TRIALNARECRUITING
Characterizing Variability in Hearing Aid Outcomes in Among Older Adults With Alzheimer's Dementia
High level of signal manipulation · Low level of signal manipulation — 2 sites
- TRIALPHASE2RECRUITING
Communication Bridge 3 Study
Communication Bridge™ · Evidence-Based Impairment Focused — 1 site
- TRIALPHASE2RECRUITING
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
BMS-986368 · Placebo — 78 sites
- TRIALPHASE3RECRUITING
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
KarXT · Placebo — 129 sites
- TRIALNAENROLLING_BY_INVITATION
Neural Mechanisms of Clinically Designed Improvisatory Music for Alzheimer's Disease
Clinically Designed Improvisatory Music — 1 site
- TRIALPHASE3RECRUITING
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
KarXT · KarX-EC · Placebo — 127 sites
- TRIALPHASE2 / PHASE3RECRUITING
ACP-204 in Adults With Alzheimer's Disease Psychosis
ACP-204 · Placebo — 150 sites
- TRIALPHASE4ENROLLING_BY_INVITATION
Quality Improvement and Practice Based Research in Neurology Using the EMR
Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description) — 1 site
- TRIALPHASE3RECRUITING
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
KarXT · Placebo — 154 sites
- TRIALPHASE3RECRUITING
Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's Disease
[F-18]Flornaptitril — 1 site
- TRIALNAENROLLING_BY_INVITATION
Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)
Sensory Stimulation System (GS120) - Active — 53 sites
- TRIALNARECRUITING
bpMedManage: Digital Technology to Support Adherence to Hypertension Medications
bpMedManage — 2 sites
- TRIALPHASE4RECRUITING
A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)
Zunveyl® — 20 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.